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Abstract
Purpose: Neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer. Dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI) enables evaluation of the tumour neovasculature that 
occurs prior to any volume change, which helps identify early treatment failures and allows prompt implementation 
of second-line therapy.
Material and methods: We conducted a prospective study in 14 patients with histopathologically proven breast cancer. 
DCE-MRI data were acquired using multisection, T1-weighted, 3D vibe sequences with fat suppression before, 
during, and after IV bolus injection (0.1 mmol/kg body weight, Gadoversetamide, Optimark). Post-processing of 
dynamic contrast perfusion data was done with the vendor’s Tissue 4D software to generate various dynamic con-
trast parameters, i.e. Ktrans, Kep, Ve, initial area under the time signal curve (IAUC), apparent diffusion coefficient 
(ADC), and enhancement curve. Patients underwent MRI examinations at baseline, and then after two cycles, and 
finally at completion of chemotherapy.
Results: Based on Sataloff criteria for pathological responses, four patients out of 14 were responders, and 10 were 
non-responders. At the 2nd MRI examination, IAUC was significantly smaller in responders than in non-responders 
(p = 0.023). When the results of the first and second MRI examinations were compared, Kep decreased from baseline 
to the second MRI (p = 0.03) in non-responders and in responders (p = 0.04). This change was statistically significant 
in both groups. The ADC values increased significantly in responders from baseline to the third MRI (p = 0.012).
Conclusions: In our study, IAUC and ADC were the only parameters that reliably differentiated responders from 
non-responders after two and three cycles of chemotherapy.
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Introduction
Neoadjuvant chemotherapy (NACT), i.e. administration 
of chemotherapy before surgical treatment, has now be-
come the standard initial treatment for locally advanced 
breast cancer. NACT has the advantages of rendering in-
operable patients operable, so they can then become can-
didates for breast-conserving surgery. NACT also allows 
in situ assessment of response to a particular chemother-
apeutic regimen, leading to a timely switch to an alterna-
tive, effective regimen in non-responders.
Physical examination, mammography, and ultra-
sonography (USG) can be used to evaluate tumour re-
sponse after chemotherapy, but they have several limita-
tions, e.g. the presence of fibrosis and necrosis hinder the 
accuracy of clinical examination. Similarly, dense breast, 
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architectural distortion, calcifications, and fibrous reac-
tion to chemotherapy hinder the interpretation of mam-
mography, whereas multifocal and in situ disease evalua-
tion is difficult with USG.
MRI is superior to physical examination, ultrasound, 
and mammography in response evaluation, and has high 
accuracy in predicting pathological complete remission 
after NACT in patients with breast cancer. It also has the 
advantage of differentiating fibrosis from tumour tissue. 
The presence of dense breast does not affect the accuracy 
of MRI, and the identification of multifocal and multicen-
tre disease is possible with this modality.
Dynamic contrast-enhanced MRI (DCE-MRI) utilises 
the changes in tumour vasculature for imaging. Neoangi-
ogenesis, i.e. formation of new blood vessels, is an early 
change in tumour development. The permeability of new-
ly formed vessels allows contrast material to leak into the 
interstitium.
The transfer constant, Ktrans, describes the transen-
dothelial transport of contrast medium by diffusion from 
the vascular space to the tumour interstitium, and provides 
a measure of vascular permeability. In tumours, Ktrans values 
are high. Over a period lasting typically several minutes to 
hours, the contrast agent diffuses back into the vasculature. 
This is described by the rate constant or Kep. Ve describes 
the extracellular extravascular space. These parameters are 
related by the following equation: Kep = Ktrans/Ve.
In patients with breast carcinoma who receive NACT, 
a significant reduction of up to a third has been shown with 
regard to both Ktrans and Kep. In addition, an increase in Ve 
of nearly a third has been shown in non-responders [1]. 
A change in Ktrans greater than 40% has been considered 
as the threshold for definitive response [2]. However, the 
results of different studies show discrepancies, with some 
studies showing little or no decrease in Ktrans or Kep fol-
lowing neoadjuvant chemotherapy [3]. In fact, one small 
study (Yu et al.) performed among 29 patients, who were 
scanned after one cycle of chemotherapy, showed that ear-
ly tumour size change is a better response predictor than 
Ktrans and Kep [4].
Semi-quantitative parameters can be calculated from 
enhancement curves, including the onset time – from in-
jection to the appearance of contrast in the tissues, max-
imum signal intensity, gradient or rate of contrast uptake 
and washout, and initial area under the time signal curve 
(IAUC). Diffusion-weighted MRI is another technique in 
which the diffusivity of water molecules is weighted in 
different tissues. Quantitative images of the diffusion co-
efficient or more exactly of the apparent diffusion coeffi-
cient (ADC) are then obtained. In malignant tissues, high 
cellular density and lipophilic cell membranes are pres-
ent, leading to low values of ADC. After chemotherapy, 
apoptosis of malignant cells occurs. Moreover, increased 
membrane permeability and increased extracellular space 
cause much higher ADC values after chemotherapy than 
before it. This change occurs earlier than changes in other 
parameters. However, due to a limited number of studies, 
further evaluation of these techniques is needed.
Material and methods
Study setting and study population
The present study was conducted at our institution among 
patients hospitalised in surgery and oncology depart-
ments from June 2013 to June 2014. The study was per-
formed with the approval of the institution’s Ethics Com-
mittee. Written consent was obtained from all patients or 
patient’s attendants. 
Inclusion criteria:
1) cytological or histological confirmation of primary 
breast carcinoma, 
2) breast tumour > 3 cm in diameter or stage IIIA or stage 
IIIB disease, 
3) no previous surgical or chemotherapeutic treatment, 
4) age between 18 and 70 years,
5) haematological values – haemoglobin > 10 g/dl, plate-
lets > 100 × 109/l, neutrophils > 1.5 × 109/l,
6) normal liver function tests (LFT),
7) glomerular filtration rate (GFR) > 30 ml/min/1.73 m2, 
using the MDRD formula. 
Sampling procedure
All consecutive patients who met the inclusion criteria 
were included in the study. MRI examinations were per-
formed, the first before the standard neoadjuvant chemo-
therapy regimen, the second after two cycles of chemo-
therapy, and the third after completion of NACT if NACT 
was given for more cycles.
Technique
MRI studies were performed using a 1.5-T, whole-body 
MRI unit (Magnetom Avanto, Siemens). An 18-G intra-
venous cannula was placed in the antecubital vein before 
prone positioning of patients on the MR table. Bilateral 
breast MRI was performed with a dedicated four-channel 
breast coil.
DCE-MRI data were obtained using multisection, 
T1-weighted, 3D vibe sequences with fat suppression be-
fore, during, and after IV bolus injection of gadoverseta-
mide (Optimark); 0.1 mmol/kg of body weight of contrast 
was given at a rate of 1.5 ml/s followed by 10 ml of saline 
flush at a  rate of 1.5 ml/ s . A  total of 30 measurements 
were taken, two before contrast, and the remaining ones 
during and after contrast injection.
Post- processing of dynamic contrast perfusion data 
was done by the vendor’s Tissue 4D software.
Tumour volume was calculated by adding the volumes 
of individual slices, calculated as follows:
Volume = area of lesion × (thickness of slice + interstice gap)
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After surgical resection, a pathological examination of 
the specimens was done and compared with post-treat-
ment MRI parameters.
A cut-off value of 50% volume change was used as 
a criterion to classify treatment response. Responders 
showed at least a 50% decrease in volume, while non- 
responders showed less than 50% decrease in tumour vol-
ume.
Pathological grading was done according to the crite-
ria of Sataloff [5]. Grade A and B (more than 50% ther-
apeutic effect) were given to responders, while Grade C 
and D (less than 50% therapeutic effect) were given to 
non-responders. 
We studied the perfusion parameters, ADC values, and 
tumour volume on MRI at baseline (first MRI), after two 
cycles (second MRI), and after completion of NACT (third 
MRI). After the last course of chemotherapy, all the selected 
patients underwent mastectomy or breast conserving thera-
py according to the standard protocols at our institute. 
The pretreatment MRI parameters, i.e. Ktrans, Kep, Ve, 
IAUC, ADC value, and tumour volume, were then cor-
related with the post-chemotherapy values. A decrease in 
tumour diameter of the pathological specimen was com-
pared with the initial baseline scan, and grading according 
to the Sataloff criteria was done.
Data were analysed using SPSS, version 17.0, for Win-
dows. The means (± SD) of all parameters at baseline 
and at completion of chemotherapy were calculated and 
compared by ANOVA. The changes in parameters were 
compared by paired t-tests for each category. Percent-
age changes in all MRI parameters were calculated and 
compared with treatment outcome/pathological speci-
men. P < 0.05 was considered as statistically significant.
Results
Sixteen patients who met our inclusion criteria were en-
rolled. One patient died after the first cycle of chemother-
apy (the cause was not reported), while another present-
ed later with metastatic disease. Those two patients were 
excluded, and the final analysis was done in 14 patients. 
Out of these 14 patients, nine received CAF-based 
NACT (cyclophosphamide, adriamycin, 5-fluorouracil), 
five received three cycles, four received four cycles, one re-
ceived ECF-based NACT (cyclophosphamide, epirubicin, 
5-fluorouracil – four cycles), and two patients received 
TAC-based CCT (docetaxel, adriamycin, 5-fluorouracil – 
three cycles). One patient received one cycle of CAF followed 
by two cycles of TAC, and one patient received two cycles 
of docetaxel alone followed by two cycles of TAC followed 
by two cycles of gemcitabine and cisplatin-based NACT. 
Baseline characteristics
The age range at presentation was 27 to 57 years. Fifty- 
seven per cent of patients had stage IIIB disease, 93% 
(13 patients) had infiltrating duct cell carcinoma (NOS), 
and 7% (1 patient) had papillary cell carcinoma on histol-
ogy (Table 1).
Baseline parameters
At baseline, MRI lesion volume varied from 9.023 cm3 
to 397 cm3 with the mean of 102.34 cm3. Ktrans varied 
from 0.04 to 0.55 with the mean of 0.25 (± 0.15), Kep var-
ied from 0.522 to 3.353 with the mean of 1.19 (± 0.83), 
Ve varied from 0.127 to 0.938 with the mean of 0.33 
(± 0.15), IAUC varied from 2.242 to 21.43 with the mean 
of 10.12 (± 5.94), and ADC varied from 534 to 1026 with 
the mean value of 789 (± 146) (Table 2).
Response to NACT
Radiological and pathological complete response (CR) 
was seen in four patients (Table 3). 
Table 1. Baseline characteristics
No. Age TNM 
status
Pre-treatment 
stage
Initial volume 
of tumor in cm3
1 45 T3N1 IIB 41
2 27 T2N2 IIB 47.7
3 42 T4BN2 IIIB 107
4 57 T3N2 IIIA 42
5 52 T4BN2M0 IIIB 167
6 46 T4BN2 IIIB 140
7 31 T3N1 IIA 141
8 38 T4BN2M0 IIIB 116
9 44 T3N1M0 IIIa 15
10 57 T4BN1M0 IIIB 91
11 38 T4BN1M0 IIIB 9.023
12 45 T4BN1M0 IIIB 397
13 50 T4BN1M0 IIIB 27
14 56 T3N2M0 IIIA 92
Table 2. Baseline lesion volume and dynamic contrast-enhanced MRI 
(DCE-MRI) parameters and apparent diffusion coefficient (ADC) (all values 
expressed in mean ± SD)
Parameter Mean SD
Lesion volume (cm3) 102.34 98.75
DCE-MRI parameters    
Ktrans (min–1) 0.25 0.15
Kep (min–1) 1.19 0.83
Ve 0.33 0.15
IAUC 10.12 5.94
ADC value (mm2/s) 789.43 146.09
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Correlation of MRI parameters with radiological response
First MRI parameters, i.e. volume, Ktrans, Kep, Ve, IAUC, 
and ADC, were not predictive of the final response to 
NACT (Table 4). At the second MRI, the IAUC value was 
significantly lower in responders than in non-responders 
(p = 0.023). None of the other parameters predicted re-
sponse to NACT (Table 5). At the third MRI, comparison 
between responders and non-responders was not possible 
because all patients who underwent the third MRI had CR. 
When changes in MRI parameters between the first 
and the last MRI in non-responders were compared, the 
Kep value changed significantly (p = 0.033). When changes 
in MRI parameters between the first and the last MRI in 
responders were compared, only the ADC value changed 
significantly (p = 0.012) (Tables 6 and 8).
On comparison of percentage changes, from the first 
to the second MRI, regarding volume, DCE parameters, 
and ADC in non-responders, the volume increased by 
8.7% (p = 0.86), Ve by 23% (p = 0.29), and ADC by 26.6% 
(p = 0.06). In contrast, Ktrans decreased by 35% (p = 0.19), 
Kep by 50.4% (p = 0.03), and IAUC by 5.58% (p = 0.83) 
(Table 6). When percentage changes from the first to 
the second MRI in volume, DCE parameters, and ADC 
were compared in responders, the volume decreased 
by 49.5% (p = 0.204), Ktrans by 17.6% (p = 0.638), Kep by 
42% (p = 0.04), IAUC by 70% (p = 0.111), and Ve by 28% 
(p = 0.422). In contrast, ADC increased by 34.5% 
(p = 0.084) (Table 7). 
Table 3. Response to neoadjuvant chemotherapy
Type 
of response
Radiological response 
(no. of patients)
Pathological response 
(no. of patients)
CR 4 4
NR 9 10
Total 13 14
CR – complete response, NR – no response
Table 4. Comparison of MRI parameters and volume among responders and non responders
Responders (CR) Non-responders (NR) p value
1st MRI
Lesion volume 84.14 ± 47.42 120.11 ± 116.31 0.570
DCE parameters    
Ktrans (min–1) 0.17 ± 0.05 0.28 ± 0.17 0.261
Kep (min–1) 1.40 ± 1.31 1.17 ± 0.63 0.660
Ve 0.32 ±0.16 0.30 ±0.13 0.775
IAUC 10.28 ± 7.47 9.49 ± 5.71 0.837
ADC (mm2/s) 845 ± 128.60 762.44 ± 161.44 0.389
2nd MRI
Lesion volume 42.45 ± 44.59 130.58 ± 125.17 0.207
DCE parameters
Ktrans (min–1) 0.14 ± 0.11 0.18 ± 0.13 0.619
Kep (min–1) 0.81 ± 1.01 0.58 ± 0.41 0.553
Ve 0.23 ± 0.14 0.37 ± 0.15 0.129
IAUC 3.07 ± 2.01 8.96 ± 4.17 0.023
ADC (mm2/s) 1138 ± 347.46 965.67 ± 250.60 0.328
Table 5. Percent change of MRI parameters among non-responder patients from baseline to first MRI
1st MRI (mean ± SD) 2nd MRI (mean ± SD) % change p value
Lesion volume 120.11 ± 116.31 130.58 ± 125.17 8.70 0.86
DCE parameters
Ktrans (min–1) 0.28 ± 0.17 0.18 ± 0.13 –35 0.19
Kep (min–1) 1.17 ± 0.63 0.58 ± 0.41 –50.4 0.03
Ve 0.30 ±0.13 0.37 ± 0.15 23.3 0.29
IAUC 9.49 ± 5.71 8.96 ± 4.17 –5.58 0.83
ADC (mm2/s) 762.44 ± 161.44 965.67 ± 250.60 26.6 0.06
RAnjna Sharma, Sanjiv Sharma, Shikha Sood et al.  
e224 © Pol J Radiol 2018; 83: e220-e228
When percentage changes, from first to third MRI, 
regarding volume, DCE parameters, and ADC were com-
pared in responders, volume decreased by 86% (p = 0.10), 
Ktrans by 0.86% (p = 0.93), Kep by 88% (p = 0.34), IAUC by 
64% (p = 0.15), and Ve increased by 19% (p = 0.28), and 
ADC by 86% (p = 0.01). 
Prediction of pathological response 
Based on Sataloff criteria for pathological responses, four 
patients out of 14 were responders, and 10 were non-re-
sponders. None of the measured parameters predicted 
pathological response.
Discussion
Volume
Partridge et al. assessed the value of MRI measurements 
of breast tumour size for predicting recurrence-free sur-
vival (RFS) in 62 patients receiving neoadjuvant chemo-
therapy. The longest tumour diameter and volume were 
measured on MRI before and after one and four cycles of 
treatment. Final change in the MRI volume (p = 0.015) 
was more predictive than change in the diameter on MRI 
(p = 0.077) or clinical examination (p = 0.27) [6]. In our 
study, we used a 50% reduction in volume as a criterion 
for response assessment; however, it could not predict the 
final pathological or radiological response.
In a study by Cho et al. (2013) 48 women with breast 
cancer were enrolled and treated with an anthracycline 
taxane regimen. Tumour size and volume, PRM char-
acteristics, and pharmacokinetic parameters (Ktrans, Kep, 
and Ve) on MR images were assessed and compared ac-
cording to the pathologic responses. Six of 48 (12%) pa-
tients showed complete response on pathology (pCR) and 
42 (88%) showed non-pathologic CR (npCR). Thirty-eight 
(79%) patients showed good radiological response, and 
10 (21%) showed a minor response. No difference in tu-
mour size, tumour volume, or pharmacokinetic param-
eters was found between the groups. In our study, vol-
ume reduction from baseline to the first MRI was 49% 
(p = 0.204), and 86% (p = 0.10) from baseline to the third 
MRI in responders, and it increased by 8% (p = 0.86) in 
non-responders from baseline to the first MRI; however, 
the changes were not statistically significant and therefore 
that study is concordant with our study [7].
Pickles et al. (2005) assed response to NACT with 
DCE-MRI in 68 patients with histologically proven breast 
cancer. MRI was performed at the initiation of NACT, ear-
ly during treatment and after the final cycle of NACT. Fol-
lowing treatment, 48 patients were classified as responders 
and 20 as non-responders based on total tumour volume 
reduction. In their study, pre-treatment volume was 
higher in responders, with a mean of 34.09 cm3, as com-
pare to non-responders, who had a volume of 29.22 cm3. 
Tumour volume changes between pre-treatment and 
early treatment time points demonstrated differences 
between responders and non-responders, with the per-
centage change being most significant (0.813%, p < 0.001). 
In our study, pre-treatment tumour volume was higher 
in non-responders. It was 84.14 ± 42.42 cm3 at baseline 
and decreased to 42.42 ± 44.49 cm3 after two cycles (49%, 
p = 0.204) in responders, and in non-responders baseline 
tumour volume was 120.11 ± 116.31 cm3 and increased 
to 130.58 ± 125.17 cm3 after two cycles of NACT (8%, 
p = 0.86). Therefore, our study found similar changes in 
responders and non-responders, but the change was not 
statistically significant [8].
In 2013, Nadrljansky et al. studied 66 patients before 
the first treatment cycle, after the second cycle, and upon 
completion of neoadjuvant chemotherapy, with regard to 
the largest tumour diameter, tumour volume, post-con-
Table 6. Percentage change of MRI parameters from 1st to 2nd MRI among responders
1st MRI( mean ± SD) 2nd MRI( mean ± SD) % change p value
Lesion volume 84.14 ± 47.42 42.45 ± 44.59 –49.5 0.204
DCE parameters
Ktrans (min–1) 0.17 ± 0.05 0.14 ± 0.11 –17.6 0.638
Kep (min–1) 1.40 ± 1.31 0.81 ± 1.01 –42.1 0.04
Ve 0.32 ±0.16 0.23 ± 0.14 –28.12 0.422
IAUC 10.28 ± 7.47 3.07 ± 2.01 –70.1 0.111
ADC (mm2/s) 845 ± 128.60 1138 ± 347.46 34.7 0.084
Table 7. Percentage change in volume, DCE parameters and apparent dif-
fusion coefficient (ADC) in responder patients from 1st to 3rd MRI (N = 3)
1st MRI 
(mean ± SD)
3rd MRI 
(mean ± SD)
% 
Change
p value
Volume (cm3) 65.57 ± 20.78 8.80 ± 3.37 –86.57 0.10
Ktrans (min–1) 0.15 ± 0.03 0.15 ± 0.09 –0.86 0.93
Kep (min–1) 1.59 ± 0.89 0.19 ± 0.03 –88 0.34
Ve 0.34 ± 0.11 0.41 ± 0.06 19.34 0.28
IAUC 11.10 ± 5.15 3.95 ± 1.69 –64.38 0.15
ADC (mm2/s) 893 ± 60.51 1666 ± 163.81 86.56 0.01
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trast enhancement, and tumour regression pattern. The 
average target lesion volume was initially 32.2 cm3 com-
pared to 17.1 cm3 after the two cycles (p < 0.01) and 
4.9 cm3 after completion of NACT (p < 0.001). The average 
target lesion volume decreased by 46.9% after two cycles 
of NACT, which was below the threshold limit of 65% 
volume decrease for response, and it decreased by 84.8% 
upon completion of NACT. In responders (n = 27) the le-
sion size upon completion of neoadjuvant chemotherapy 
was significantly smaller than in non-responders (1.5 ± 
0.6 vs. 3.2 ± 0.9 cm; p < 0.001), as was the volume (1.2 vs. 
11.0 cm3; p < 0.001) [9]. Similarly, in our study the initial 
lesion size in responders was 65 cm3 as compared to 8.8 
cm3 at completion of NACT. The average target volume de-
creased by 49% (p = 0.21) after two cycles of NACT, which 
was near to the threshold limit of 50% for response, and it 
decreased by 86% (p = 0.857) after completion of NACT. In 
non-responders, the volume increased by 8% (p = 0.86%), 
although this change was not statistically significant.
Padhani et al. performed a prospective study to doc-
ument changes in contrast agent kinetics in patients with 
primary breast cancer treated with NACT. Twenty-five 
patients underwent DCE-MRI examination before ini-
tiating treatment, after the first cycle and then after the 
second cycle of NACT. After the second cycle of NACT, 
in five of six non-responders the tumour size increased, 
compared with a decrease in eight out of nine responders. 
Reductions in transfer constant range were also observed 
in responders with regard to both clinical and patholog-
ical assessments. They concluded that reductions in the 
volume of the primary tumour best predict clinical and 
pathologic response of breast cancer after one cycle of ne-
oadjuvant chemotherapy [3]. Our study showed similar 
trends with reduction in tumour volume in responders 
(49%, p = 0.204) and an increase in non-responders (8%, 
p = 0.86%) after two cycles of NACT, although this differ-
ence was not significant statistically.
Tissue parametric imaging
In 2002, 21 patients with locally advanced breast cancer 
on NACT were studied by Wasser et al. [10], who evalu-
ated changes in both size and contrast enhancement of 
breast tumours during neoadjuvant chemotherapy using 
dynamic MRI. A reduction in tumour size after chemo-
therapy of more than 25% was associated with a decrease 
in both parameters (Kep, p < 0.002, amplitude, p < 0.006). 
Kep began to drop after the first cycle of chemotherapy. 
A clear reduction in tumour size was only noted after the 
third cycle. In our study, in responders there was a statisti-
cally significant reduction in Kep with reduction in tumour 
size. A significant reduction in Kep values was also seen 
in non-responders, although the tumour volume in-
creased. This finding is in disagreement with the study 
of Wasser et al., in which changes were significant only 
in responders. 
In 2007, Yu et al. [4] investigated 29 patients with 
invasive breast cancer. Tumour size, Ktrans, and Kep were 
used to predict final clinical response to NACT. Doxo-
rubicin and cyclophosphamide (AC) chemotherapy was 
given every two weeks. Significant correlation was seen 
between early changes in tumour size and both Ktrans and 
Kep. Early tumour size change on MRI after one cycle was 
found to be a better response predictor than either Ktrans or 
Kep. In contrast to this study, our study showed significant 
correlation between early changes in Kep, but the change 
was significant among non-responders as well. In contrast 
to that study, no significant correlation was seen between 
early change in volume and Ktrans (p = 0.21 and p = 0.638, 
respectively).
Pickles et al. noted that both Ktrans and Kep showed 
a  significant reduction in responders between the 
pre-treatment and early treatment time points. In con-
trast, a significant increase in Ve was seen in non-re-
sponders. Contrary to our study, no significant reduction 
in Ktrans (p = 0.638) was seen in pre-treatment and early 
treatment endpoints in responders. Kep decreased signif-
icantly in both responders and non-responders. A 23% 
increase in Ve was seen among non-responders; however, 
it was not statistically significant (p = 0.291) [11].
In 2007, Thukral et al. [12] retrospectively compared 
three dynamic contrast-enhanced MRI examinations to 
determine the parameters or a combination of parame-
ters that were most strongly associated with changes in 
tumour microvasculature during treatment with beva-
cizumab alone and bevacizumab plus chemotherapy in 
patients with inflammatory or locally advanced breast 
cancer. Twenty-one women were enrolled. In 19 patients, 
using a whole-tumour region of interest, the authors ob-
served a significant decrease in the median values of the 
three following parameters measured from baseline to the 
first cycle: forward transfer rate constant (Ktrans) (−34% 
relative change, p = 0.003), backflow compartmental rate 
constant extravascular and extracellular to constant (Kep) 
(−15% relative change, p < 0.001), and integrated area 
under the gadolinium concentration curve (IAUGC) at 
180 seconds (−23% relative change, p = 0.009). In our 
study, no significant decrease in Ktrans (–17.6% relative 
change, p = 0.638), Ve (–28.1% relative change, p = 0.422), 
IAUC (–70.1% relative change, p = 0.111) was seen after 
the third MRI. Only the decrease in Kep was significant 
(–42.1% relative change, p = 0.04).
Bazelaire et al. [13] performed a retrospective study 
in 24 women with locally advanced breast cancer. MRI 
was performed before NACT and after eight cycles of 
treatment. This was followed by surgery less than four 
weeks after the last course of chemotherapy. Changes in 
kinetic parameters after treatment were compared with 
final pathologic response graded as non-responding 
(< 50% therapeutic effect), partially responding (> 50% 
therapeutic effect), and completely responding. Changes 
in Ve and Ktrans were significantly different between non 
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(n = 11), partial (n = 7), and complete (n = 6) responders 
(p = 0.0092 and p = 0.0398, respectively). A decrease in 
Ve of more than –72% and more than –84% for Ktrans re-
sulted in 73% sensitivity for identifying non-responders 
(specificity 92% and 77%, respectively). A decrease in Ve 
of more than –87% helped to identify complete respond-
ers. In contrast, our study found no significant difference 
in the parameters when baseline scan was compared with 
the final pathological response between responders and 
non-responders (Ktrans 0.15 ± 0.05 vs. 0.27 ± 0.16, Kep 1.59 
± 1.53 vs. 1.08 ± 0.61, Ve 0.34 ± 0.19 vs. 0.32 ± 0.15, IAUC 
11.10 ± 8.93 vs. 9.86 ± 5.44 in responders and non-re-
sponders, respectively; with p = 0.242, 0.365, 0.844, and 
0.763 for Ktrans, Kep, Ve, and IAUC, respectively). In addi-
tion, Ve increased by 19% between the first and the final 
MRI among responders (p = 0.28). On the second MRI, 
Ve decreased by 28% (0.422) among responders and in-
creased by 23% (p = 0.291) in non-responders; the chang-
es were statistically significant. 
Johansen et al. [14] evaluated DCE-MRI in patients 
scheduled for NACT (n = 24) before and after the first 
treatment cycle. Clinical response was evaluated after 
completed NACT. Relative signal intensity (RSI) and 
AUC were calculated from DCE-curves and compared 
with clinical treatment response. They found that RSI and 
AUC were reduced after only one cycle of NAC in patients 
with clinical treatment response (p = 0.02 and p = 0.08). 
Our results are consistent with that study, but after 
two cycles of NACT, IAUC was a significant predictor of 
response to chemotherapy. The mean IAUC value in re-
sponders was 3.07 ± 2.01 and 8.96 ± 4.17 in non-respond-
ers (p = 0.023). Although our study group was small, 
IAUC showed an early change in responding patients. It 
was a good predictor of response; however, comparison 
at the third MRI was not possible because none of the 
non-responders underwent the third MRI.
Diffusion-weighted imaging
Park et al. [15], in a retrospective study (2010), evaluated 
53 consecutive women with invasive breast cancer, who 
underwent NACT. Both DWI MR imaging and DCE-
MRI were performed at 1.5 T before and after NACT 
prior to surgery. Pre-treatment ADCs and percentage 
increases in ADC after chemotherapy in responders and 
non-responders were compared. Patients with reduced 
tumour diameter of at least 30% after chemotherapy at 
DCE-MRI were defined as responders. After chemother-
apy, 36 patients were classified as responders, and 17 were 
classified as non-responders. The pre-treatment mean 
ADC of responders was significantly lower than that of 
non-responders. Furthermore, the mean percentage ADC 
increase of responders (47.9%) was higher than that of 
non-responders (18.1%). The best pre-treatment ADC 
cutoff for differentiation between responders and non-re-
sponders was 1.17 × 103 mm2/s. 
In our study, the ADC values at baseline were higher 
(845 ± 128) in than in non-responders (762.44 ± 161.44, 
p = 0.389). This finding is in disagreement with the study 
by Park et al. The ADC value in responding patients in-
creased from 845 ± 128 to 1138 ± 347 at the second MRI 
(34%, p = 0.084) and then to 1666 ± 284 at the third MRI 
(86.6%). At the third MRI, this change was significant 
(p = 0.01). In contrast, the change in ADC values in 
non-responders was not significant (762.44 ± 161.44 at 
the first MRI to 965.67 ± 250.60 at the second MRI). This 
aspect of our study is in line with the study by Park et al.
Kawamura et al. [16] evaluated 11 breast cancer pa-
tients (12 lesions) scheduled for NACT. The patients were 
examined with MRI prior to and after the first and fourth 
course of anthracycline-containing chemotherapy and af-
ter subsequent taxane-containing chemotherapy. Lesions 
were divided into two types – the mass type and non-mass 
type, based on contrast MRI performed prior to chemo-
therapy. Among eight patients with mass type lesions, six 
were responders and two were non-responders. Responders 
showed either an increased apparent diffusion coefficient 
(ADC) or volume reduction after the first course of NACT, 
whereas non-responders showed neither (p < 0.005). Of 
the four patients with non-mass type lesions, two were re-
sponders and two were non-responders. Changes in ADC 
or volume after the first course of NACT may indicate che-
mosensitivity of mass type breast cancer lesions.
In our study, responders also showed increased ADC 
(34%, p = 0.084) and volume reduction (49%, p = 0.204), 
but it was not statistically significant after two cycles of 
NACT, whereas non-responders showed a 26% decrease 
in ADC (p = 0.06) with an 8.7% increase in volume 
(p = 0.857).
Jensen et al. [17] evaluated DWI and DCE-MRI in 
15 breast cancer patients, performed before and after one 
cycle of NACT. MRI tumour diameter and volume, ap-
parent diffusion coefficient (ADC), and kinetic parame-
ters (Ktrans and Ve) were evaluated. The reliability of ADC 
before NACT was assessed. The reliability of ADC values 
was high, with an intraclass correlation coefficient of 0.84 
(p = 0.001). After one cycle of NACT, MRI tumour diam-
eter (8%, p = 0.005) and tumour volume (30%, p = 0.008) 
were reduced in all patients, while the mean ADC values 
increased (0.12 mm2/s, p = 0.008). Similarly, in our study, 
after two cycles of NACT, in responders, tumour volume 
decreased from 84.14 ± 47.22 to 42.45 ± 44.59 (49%, 
p = 0.204), while the mean ADC value increased from 845 
± 128 to 1138 ± 347 (34%, p = 0.084), but these changes 
were not statistically significant.
Pathological response
In the study by Loo et al. [18], dynamic contrast-enhanced 
MRI was performed before chemotherapy and after two 
chemotherapy cycles in 54 breast cancer patients. Imag-
ing was correlated with final pathology. The change in the 
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largest diameter of late enhancement during chemother-
apy was the single most predictive MRI characteristic for 
tumour response in a multivariate analysis. A decrease 
in the largest diameter of less than 25% during chemo-
therapy was most indicative of residual tumour at final 
pathology. Using this criterion, the fraction of unfavour-
able responders indicated by MRI was 41% (22/54). Ap-
proximately half (44%, 14/32) of the patients who showed 
favourable response at MRI achieved complete remission 
at pathology. Conversely, 95% (21/22) of patients who 
showed unfavourable response at MRI had residual tu-
mour at pathology. 
Likewise, in our study the concordance between the 
pathological and radiological response rate was good, with 
four out of the four radiological responders showing patho-
logical CR. Thus, the coherence between the two modali-
ties was found to be good (100%). However, none of the 
parameters predicted pathological response when base-
line MRI parameters including volume, Ktrans (p = 0.489), 
Kep (p = 0.242), Ve (p = 0.365), IAUC (p = 0.844), and ADC 
(p = 0.175) were compared with the final pathological re-
sponse among responders and non-responders.
In 2008, Ah See et al. [19] examined 37 patients with 
breast cancer, who were to receive six cycles of ECF-based 
chemotherapy (epirubicin, cisplatin, and 5-fluorouracil). 
Their patients underwent DCE-MRI studies before the in-
itiation of chemotherapy and after two cycles of therapy. 
Twenty-eight patients were evaluated with regard to re-
sponse (19 clinical responders and nine non-responders). 
Changes in the DCE-MRI kinetic parameters Ktrans and 
Kep were significantly correlated with both final clinical 
and pathologic response. The change in Ktrans was the best 
predictor of pathologic response, correctly identifying 
94% of non-responders and 73% of responders. Interest-
ingly, the change in MRI-derived tumour size did not pre-
dict pathologic response. In our study, Ktrans, Kep, Ve, and 
IAUC were not predictive of the final pathologic response 
(p = 0.242, p = 0.265, p = 0.844, p = 0.763, respective-
ly). However, in line with that study, the change in MRI- 
derived tumour volume did not predict pathologic re-
sponse (p = 0.489).
In a recent review by Galban et al., of three different 
prospective clinical trials [20], in which a total of 39 pa-
tients with LABC underwent DW-MRI prior to and at 
3-7 days, 8-11 days, and 35 days post-treatment initiation, 
the mean tumour ADC values generated from patient 
test-retest examinations were found to be very reproduc-
ible. A parametric response map was calculated and was 
found to be predictive of the outcome at day 35 (AUC = 
0.770, p = 0.05). 
In another study by Huang et al. [21], DCE-MRI data 
acquired in one centre from 10 patients with breast cancer 
before and after the first cycle of neoadjuvant chemother-
apy were reviewed with 12 software tools. Nearly all tools 
provided early prediction of therapy response using the 
mean tumour Ktrans and Kep (= Ktrans/Ve, intravasation rate 
constant) after the first therapy cycle. The authors con-
cluded that the algorithm parameter variation did not 
significantly affect the utility of DCE-MRI for assessing 
therapy response.
The small study group consisting of 14 patients was 
a limiting factor of our study and thus the results need 
to be interpreted in a larger study for validation. More-
over, the chemotherapy regimens used in our study were 
varied, and the number of chemotherapy cycles was not 
uniform.
Long acquisition times and uncomfortable positioning 
of patients was also a significant issue, with eight of the 
14 patients complaining of the long and uncomfortable 
positioning, although none refused to participate. 
Conclusions
DCE-MRI was performed in 14 patients to search for pre-
dictors of response to NACT in locally advanced breast 
cancer. MRI was done at baseline, after two cycles, and fi-
nally after completion of chemotherapy. At the second MRI 
examination, IAUC was found to be significantly lower in 
responders than in non-responders. The decrease in Kep 
values was statistically significant in both responders and 
non-responders. An increase in ADC values was statisti-
cally significant from the first to the third MRI in respond-
ers, and it also increased in non-responders, albeit not 
significantly. In our study, IAUC and ADC were the only 
parameters that could reliably differentiate responders from 
non-responders after two and three cycles of chemotherapy.
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